Month: May 2024

Exhibit 99.1 SHANGHAI, China, May 20, 2024 (GLOBE NEWSWIRE) — ECARX Holdings Inc. (Nasdaq: ECX) (“ECARX” or the “Company”), a global mobility tech provider, today announced unaudited financial results for the quarter ended March 31, 2024. “The strong growth momentum that we picked up last year continued into the first quarter with revenues increasing 21% year-over-year,” commented ECARX Chairman and CEO Ziyu Shen. “The development of software-defined vehicles and their underpinning technologies will determine the winners in this next stage of the auto revolution. Continued product innovation and a strong ecosystem of partnerships are key to capitalizing on this opportunity. The multiple ground-breaking automotive intelligence solutions that we unveiled during the quarter, and the synergies being created by our growing number of...

CHICAGO, May 20, 2024 (GLOBE NEWSWIRE) — Vivid Seats Inc. (NASDAQ: SEAT) (“Vivid Seats”), a leading marketplace that utilizes its technology platform to connect millions of buyers with thousands of ticket sellers across hundreds of thousands of events each year, today announced that Stan Chia, Chief Executive Officer, and Lawrence Fey, Chief Financial Officer, will be presenting at William Blair’s 2024 Growth Stock Conference on Wednesday, June 5, 2024 at 8:40 a.m. CT. A live webcast of the presentation will be accessible on the Vivid Seats Investor Relations website at https://investors.vividseats.com/ under “News & Events.” About Vivid SeatsFounded in 2001, Vivid Seats is a leading online ticket marketplace committed to becoming the ultimate partner for connecting fans to the live events, artists, and teams they love. Based...

New production process will be developed based on Pluri’s proprietary 3D cell expansion technology Human breast milk oligosaccharides are known to shape the gut microbiota and thus provide health benefits to adults Global elderly nutrition market is valued at $25.2 billion, estimated to reach $39.7 billion in less than 10 yearsHAIFA, Israel, May 20, 2024 (GLOBE NEWSWIRE) — Leading biotechnology company Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”), which transforms cells into solutions that promote global wellbeing and sustainability, today announced a strategic collaboration with Wilk Technologies Ltd. (TASE: WILK) (“Wilk Technologies” or “Wilk”), a developer of authentic, cell-cultured human and animal milk components. By combining Pluri’s cutting-edge 3D cell-expansion technology with Wilk’s expertise...

GUANGZHOU, China, May 20, 2024 (GLOBE NEWSWIRE) — Highest Performances Holdings Inc. (NASDAQ: HPH) (“HPH” or the “Company”), today announced that it will release its unaudited financial results for the first half of its fiscal year 2024 ended December 31, 2023 on May 30, 2024. Senior management of the Company will host a bilingual conference call in English and Chinese to discuss the Company’s unaudited financial results and business development for the first half of its fiscal year 2024 ended December 31, 2023. Details for the conference call are as follows:Date/Time: Thursday, May 30, 2024 at 9:00 PM U.S. Eastern Time  (Friday, May 31, 2024 at 9:00 AM Beijing/Hong Kong Time)Conference Title: Highest Performances Holdings Inc. Six Months Ended December 31, 2023 Earnings Call   Please pre-register online in advance...

Presentations highlight new VCIEL scale to measure small intestinal mucosal health and research from rich database of latiglutenase Phase 2 clinical trials BOCA RATON, Fla., May 20, 2024 (GLOBE NEWSWIRE) — Entero Therapeutics, Inc., (NASDAQ: ENTO), (“Entero Therapeutics” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, yesterday presented two posters on celiac disease research at the 2024 Digestive Disease Week (DDW 2024) Conference in Washington, D.C. The presentations draw upon research from the robust clinical program investigating latiglutenase, an oral biotherapeutic being developed as a potentially first-in-class, targeted, oral biotherapeutic for celiac disease (CeD). The results from these presentations demonstrate...

Arecor Therapeutics plc(“Arecor” or “the Company”) AT278 ULTRA-CONCENTRATED ULTRA-RAPID ACTING INSULIN DEMONSTRATES SUPERIORITY IN PHASE I CLINICAL TRIAL IN OVERWEIGHT AND OBESE PEOPLE WITH TYPE 2 DIABETESAT278 demonstrates significantly accelerated PK/PD profile compared to NovoRapid® and Humulin® R U-500 in people with Type 2 Diabetes and high BMI Confirms previous trial results in people with Type 1 diabetes, demonstrating AT278 can maintain fast and superior onset of action and glucose lowering profile irrespective of diabetes type and BMI Enables delivery of a highly concentrated, low volume injection, offering more effective mealtime glucose control to meet growing unmet need in patients requiring high daily doses of insulin Creates potential to be the first, and only, ultra-concentrated (500 U/mL) ultra-rapid insulin product...

Ageas and Taiping deepen cooperation in pension solutions Ageas announces today that following confirmation of its participation in the capital increase tender in November 2023, an agreement has been concluded with China Taiping Insurance Holdings (CTIH) to subscribe to the capital increase of its wholly controlled subsidiary Taiping Pension Co., Ltd (“TPP”) for a total consideration of RMB 1,075 million (around EUR 137 million)*. After closing of the transaction Ageas will hold 10% of the enlarged share capital of TPP. The investment in TPP will allow Ageas to tap into the significant growth potential of the Chinese pension market, capitalising on the increasing demand for personal pension products in China. It also helps Ageas to strengthen its presence in the largest growth market in Asia, diversify its business offerings, and consolidate...

SHENZHEN, China, May 20, 2024 (GLOBE NEWSWIRE) — Aesthetic Medical International Holdings Group Limited (Nasdaq: AIH) (the “Company” or “AIH”), a leading provider of aesthetic medical services in China, today announced that it has received a determination letter of the Hearings Panel (the “Panel”) of The Nasdaq Capital Market (“Nasdaq”) dated May 17, 2024, notifying the Company that the Panel determined to delist the Company’s securities from Nasdaq, due to the failure to satisfy the continued listing conditions as previously disclosed. As a result, the Company expects that its securities will be suspended from trading at the open of business on May 21, 2024 and delisted from Nasdaq after the completion of Nasdaq’s filing of a Form 25 Notification of Delisting with the Securities and Exchange Commission after all appeal periods...

BAUDETTE, Minn., May 20, 2024 (GLOBE NEWSWIRE) — ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Kionex® (Sodium Polystyrene Sulfonate Suspension USP) for Oral or Rectal use. Kionex® Suspension is the only commercially available therapeutically equivalent to the reference listed drug (RLD) SPS® Suspension for Oral or Rectal use. “The launch of Kionex® Suspension for Oral or Rectal use exemplifies our capability to bring complex generics with limited market competition to our customers and patients in need. This launch is especially meaningful given the complexity of the development and is a testament to the tireless efforts of our strong R&D team to meet the updated guidance from the U.S. Food and Drug Administration,” stated Nikhil Lalwani, President and Chief Executive Officer...

Bayport Management Ltd announces standstill agreement and is in constructove negotiations with creditiors to address its capital structure, cash interest obligations and debt maturitiesAttachmentsBayport Management Limited – Market Announcement – 20 May 2024Bayport Management Limited – Market Announcement – 20 May 2024